| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 22 | 2022 | 189 | 3.730 |
Why?
|
| Ovarian Neoplasms | 29 | 2020 | 607 | 3.250 |
Why?
|
| Uterine Neoplasms | 11 | 2023 | 80 | 2.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 8 | 2018 | 72 | 1.520 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 146 | 1.260 |
Why?
|
| Female | 72 | 2025 | 15634 | 1.120 |
Why?
|
| Genital Neoplasms, Female | 3 | 2020 | 67 | 0.880 |
Why?
|
| Hysterectomy | 8 | 2025 | 86 | 0.860 |
Why?
|
| Aged | 38 | 2025 | 5599 | 0.850 |
Why?
|
| Middle Aged | 41 | 2025 | 7416 | 0.820 |
Why?
|
| Peritoneal Neoplasms | 4 | 2017 | 80 | 0.810 |
Why?
|
| Humans | 72 | 2025 | 28884 | 0.810 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2021 | 9 | 0.790 |
Why?
|
| Carcinoma, Endometrioid | 6 | 2019 | 41 | 0.790 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 415 | 0.760 |
Why?
|
| Neoplasm Staging | 21 | 2023 | 480 | 0.750 |
Why?
|
| Gynecology | 2 | 2020 | 60 | 0.710 |
Why?
|
| Liposarcoma | 1 | 2021 | 2 | 0.710 |
Why?
|
| Lipoma | 1 | 2021 | 11 | 0.700 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 51 | 0.670 |
Why?
|
| Military Medicine | 1 | 2020 | 3 | 0.650 |
Why?
|
| Bombyx | 1 | 2019 | 2 | 0.630 |
Why?
|
| Obstetrics | 1 | 2020 | 51 | 0.620 |
Why?
|
| Genetic Variation | 1 | 2019 | 246 | 0.560 |
Why?
|
| Phylogeny | 1 | 2019 | 493 | 0.520 |
Why?
|
| Carcinoma, Papillary | 2 | 2008 | 18 | 0.520 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2025 | 304 | 0.500 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2006 | 5 | 0.490 |
Why?
|
| Neoplasm, Residual | 7 | 2018 | 32 | 0.480 |
Why?
|
| Progesterone | 5 | 2016 | 130 | 0.460 |
Why?
|
| Widowhood | 1 | 2014 | 1 | 0.450 |
Why?
|
| Marriage | 1 | 2014 | 8 | 0.450 |
Why?
|
| Vaginal Diseases | 1 | 2014 | 5 | 0.450 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2014 | 21 | 0.430 |
Why?
|
| Postoperative Complications | 3 | 2017 | 634 | 0.430 |
Why?
|
| Paclitaxel | 6 | 2019 | 200 | 0.430 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2022 | 33 | 0.420 |
Why?
|
| Cisplatin | 5 | 2017 | 186 | 0.420 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2019 | 347 | 0.420 |
Why?
|
| SEER Program | 4 | 2017 | 47 | 0.400 |
Why?
|
| Carcinosarcoma | 3 | 2020 | 31 | 0.400 |
Why?
|
| Teratoma | 1 | 2013 | 17 | 0.400 |
Why?
|
| Calcinosis | 1 | 2013 | 25 | 0.400 |
Why?
|
| Survival Rate | 10 | 2025 | 432 | 0.390 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2016 | 20 | 0.390 |
Why?
|
| Health Status Disparities | 4 | 2020 | 66 | 0.380 |
Why?
|
| Ultrasonography | 1 | 2013 | 243 | 0.370 |
Why?
|
| Gynecologic Surgical Procedures | 4 | 2015 | 35 | 0.360 |
Why?
|
| Carcinoma | 3 | 2019 | 74 | 0.360 |
Why?
|
| Calcitriol | 3 | 2016 | 3 | 0.360 |
Why?
|
| Survival Analysis | 7 | 2023 | 288 | 0.350 |
Why?
|
| Adult | 19 | 2025 | 8030 | 0.340 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 2065 | 0.340 |
Why?
|
| Prognosis | 10 | 2022 | 811 | 0.330 |
Why?
|
| Aortitis | 1 | 2010 | 3 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 433 | 0.330 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2019 | 170 | 0.320 |
Why?
|
| Algorithms | 1 | 2013 | 431 | 0.320 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 48 | 0.320 |
Why?
|
| Deoxycytidine | 1 | 2010 | 67 | 0.320 |
Why?
|
| Early Detection of Cancer | 3 | 2019 | 137 | 0.310 |
Why?
|
| Ovary | 2 | 2016 | 72 | 0.310 |
Why?
|
| Proteomics | 9 | 2019 | 197 | 0.300 |
Why?
|
| Carboplatin | 4 | 2018 | 121 | 0.300 |
Why?
|
| United States | 8 | 2025 | 2225 | 0.300 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2018 | 33 | 0.300 |
Why?
|
| Ovarian Cysts | 1 | 2008 | 6 | 0.290 |
Why?
|
| Cystadenoma, Serous | 1 | 2008 | 3 | 0.280 |
Why?
|
| Lymph Node Excision | 2 | 2011 | 101 | 0.280 |
Why?
|
| Neoplasm Grading | 9 | 2018 | 105 | 0.280 |
Why?
|
| Nestin | 3 | 2016 | 10 | 0.270 |
Why?
|
| Disease-Free Survival | 8 | 2017 | 236 | 0.270 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 97 | 0.270 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 108 | 0.270 |
Why?
|
| Palliative Care | 1 | 2008 | 86 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2020 | 118 | 0.260 |
Why?
|
| Adenocarcinoma | 4 | 2025 | 300 | 0.260 |
Why?
|
| Cell Cycle Proteins | 3 | 2019 | 187 | 0.260 |
Why?
|
| Vitamin D3 24-Hydroxylase | 2 | 2016 | 4 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 336 | 0.250 |
Why?
|
| Medical Oncology | 2 | 2020 | 98 | 0.230 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 686 | 0.220 |
Why?
|
| Transforming Growth Factor beta | 2 | 2016 | 79 | 0.220 |
Why?
|
| Retrospective Studies | 10 | 2022 | 2635 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 151 | 0.220 |
Why?
|
| Cohort Studies | 7 | 2025 | 897 | 0.210 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2007 | 216 | 0.210 |
Why?
|
| Cell Line, Tumor | 10 | 2019 | 1351 | 0.210 |
Why?
|
| Ascites | 2 | 2017 | 19 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 472 | 0.200 |
Why?
|
| Mutation | 4 | 2021 | 867 | 0.200 |
Why?
|
| CA-125 Antigen | 3 | 2017 | 19 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2008 | 63 | 0.190 |
Why?
|
| Treatment Outcome | 6 | 2019 | 2426 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 676 | 0.180 |
Why?
|
| Endometrium | 3 | 2019 | 39 | 0.180 |
Why?
|
| Proteogenomics | 1 | 2021 | 1 | 0.180 |
Why?
|
| Fumarate Hydratase | 1 | 2021 | 4 | 0.180 |
Why?
|
| Leiomyomatosis | 1 | 2021 | 2 | 0.180 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2021 | 6 | 0.170 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 75 | 0.170 |
Why?
|
| Dobutamine | 1 | 2001 | 7 | 0.170 |
Why?
|
| Age Factors | 5 | 2020 | 737 | 0.170 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2001 | 20 | 0.170 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2001 | 8 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2019 | 19 | 0.170 |
Why?
|
| Myocardial Contraction | 1 | 2001 | 62 | 0.170 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 302 | 0.170 |
Why?
|
| Pelvis | 1 | 2020 | 38 | 0.170 |
Why?
|
| Proteome | 1 | 2021 | 79 | 0.170 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2001 | 64 | 0.160 |
Why?
|
| Myocardial Ischemia | 1 | 2001 | 73 | 0.160 |
Why?
|
| Leiomyosarcoma | 1 | 2020 | 10 | 0.160 |
Why?
|
| Risk Factors | 4 | 2021 | 2127 | 0.160 |
Why?
|
| Salpingo-oophorectomy | 1 | 2019 | 3 | 0.160 |
Why?
|
| Genes, BRCA2 | 2 | 2017 | 10 | 0.160 |
Why?
|
| Genes, BRCA1 | 2 | 2017 | 12 | 0.160 |
Why?
|
| Exercise Test | 1 | 2001 | 249 | 0.160 |
Why?
|
| Likelihood Functions | 1 | 2019 | 27 | 0.160 |
Why?
|
| Ovariectomy | 2 | 2017 | 53 | 0.160 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 379 | 0.150 |
Why?
|
| Vaccines, Subunit | 1 | 2019 | 7 | 0.150 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2019 | 6 | 0.150 |
Why?
|
| Metformin | 1 | 2019 | 36 | 0.150 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 49 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2019 | 404 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 147 | 0.150 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 33 | 0.150 |
Why?
|
| Genetic Loci | 1 | 2019 | 77 | 0.150 |
Why?
|
| Laparoscopy | 2 | 2017 | 156 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 190 | 0.140 |
Why?
|
| Chromatography, Liquid | 5 | 2019 | 79 | 0.140 |
Why?
|
| Base Sequence | 1 | 2019 | 589 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 194 | 0.140 |
Why?
|
| Choriocarcinoma | 1 | 2018 | 6 | 0.140 |
Why?
|
| A Kinase Anchor Proteins | 2 | 2015 | 4 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 5 | 2019 | 117 | 0.140 |
Why?
|
| Signal Transduction | 4 | 2019 | 1469 | 0.130 |
Why?
|
| ROC Curve | 1 | 2017 | 144 | 0.130 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2017 | 7 | 0.130 |
Why?
|
| Salpingectomy | 1 | 2017 | 8 | 0.130 |
Why?
|
| Choice Behavior | 1 | 2017 | 28 | 0.130 |
Why?
|
| Pelvic Neoplasms | 1 | 1996 | 8 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2017 | 128 | 0.130 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 15 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2016 | 32 | 0.130 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1996 | 44 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 32 | 0.120 |
Why?
|
| Femoral Artery | 1 | 1996 | 58 | 0.120 |
Why?
|
| Nuclear Localization Signals | 1 | 2015 | 9 | 0.120 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 24 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 226 | 0.120 |
Why?
|
| Mitochondrial Proteins | 2 | 2013 | 80 | 0.120 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 483 | 0.110 |
Why?
|
| Follicular Phase | 1 | 2015 | 8 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2017 | 255 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2017 | 163 | 0.110 |
Why?
|
| Luteal Phase | 1 | 2015 | 7 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2015 | 138 | 0.110 |
Why?
|
| Marital Status | 1 | 2014 | 16 | 0.110 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 16 | 0.110 |
Why?
|
| Regression Analysis | 3 | 2017 | 211 | 0.110 |
Why?
|
| Suppuration | 1 | 2014 | 5 | 0.110 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2014 | 8 | 0.110 |
Why?
|
| Stromal Cells | 1 | 2015 | 62 | 0.110 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2014 | 53 | 0.110 |
Why?
|
| Collagen Type XI | 1 | 2013 | 1 | 0.100 |
Why?
|
| Vaginal Neoplasms | 1 | 2013 | 12 | 0.100 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2013 | 4 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 249 | 0.100 |
Why?
|
| Obesity | 1 | 2019 | 701 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2015 | 152 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 46 | 0.100 |
Why?
|
| Bevacizumab | 2 | 2018 | 106 | 0.100 |
Why?
|
| Receptors, Calcitriol | 1 | 2013 | 6 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2013 | 86 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 166 | 0.100 |
Why?
|
| Abdomen | 1 | 2013 | 41 | 0.100 |
Why?
|
| Gene Expression Profiling | 4 | 2017 | 465 | 0.100 |
Why?
|
| Apoptosis | 2 | 2015 | 780 | 0.100 |
Why?
|
| Animals | 5 | 2019 | 10699 | 0.100 |
Why?
|
| Cadherins | 3 | 2019 | 24 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2015 | 265 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 123 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2012 | 35 | 0.090 |
Why?
|
| Publishing | 1 | 2012 | 34 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2012 | 93 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2015 | 523 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2017 | 104 | 0.090 |
Why?
|
| Laser Capture Microdissection | 1 | 2011 | 9 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2019 | 1280 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2014 | 302 | 0.080 |
Why?
|
| Fever of Unknown Origin | 1 | 2010 | 2 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 27 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2007 | 314 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 100 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2019 | 825 | 0.080 |
Why?
|
| Paracentesis | 1 | 2008 | 5 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2008 | 43 | 0.070 |
Why?
|
| Infusions, Parenteral | 1 | 2008 | 37 | 0.070 |
Why?
|
| Gene Expression | 3 | 2015 | 417 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2021 | 739 | 0.070 |
Why?
|
| Immunomagnetic Separation | 1 | 2007 | 4 | 0.070 |
Why?
|
| Ascitic Fluid | 1 | 2007 | 11 | 0.070 |
Why?
|
| Age of Onset | 2 | 2018 | 72 | 0.070 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2013 | 37 | 0.070 |
Why?
|
| Laparotomy | 2 | 2017 | 35 | 0.070 |
Why?
|
| Young Adult | 3 | 2019 | 2839 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2017 | 30 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 612 | 0.060 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 35 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 22 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2016 | 106 | 0.060 |
Why?
|
| Receptors, Progesterone | 2 | 2016 | 17 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2006 | 21 | 0.060 |
Why?
|
| Antibodies, Bispecific | 1 | 2006 | 12 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 65 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2005 | 77 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 485 | 0.060 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2025 | 12 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 98 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2016 | 202 | 0.060 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2016 | 120 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 465 | 0.050 |
Why?
|
| Quality of Life | 2 | 2019 | 521 | 0.050 |
Why?
|
| Culture Media | 2 | 2014 | 99 | 0.050 |
Why?
|
| Cell Survival | 2 | 2016 | 419 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2017 | 485 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2025 | 165 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2014 | 140 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1032 | 0.050 |
Why?
|
| Survivorship | 1 | 2022 | 16 | 0.050 |
Why?
|
| Counseling | 1 | 2022 | 57 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2015 | 668 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 787 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2001 | 9 | 0.040 |
Why?
|
| Adolescent | 2 | 2019 | 3197 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 2001 | 32 | 0.040 |
Why?
|
| Angina Pectoris | 1 | 2001 | 109 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 1613 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 163 | 0.040 |
Why?
|
| Mice | 3 | 2017 | 4808 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 32 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 59 | 0.040 |
Why?
|
| Complement Factor B | 1 | 2019 | 3 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 5 | 0.040 |
Why?
|
| Transferrin | 1 | 2019 | 10 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2019 | 10 | 0.040 |
Why?
|
| HLA-A2 Antigen | 1 | 2019 | 18 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 80 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 134 | 0.040 |
Why?
|
| Catalase | 1 | 2019 | 49 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 82 | 0.040 |
Why?
|
| Nomograms | 1 | 2019 | 9 | 0.040 |
Why?
|
| Platinum Compounds | 1 | 2019 | 14 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2019 | 80 | 0.040 |
Why?
|
| Heart Rate | 1 | 2001 | 382 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 261 | 0.040 |
Why?
|
| HIV Infections | 1 | 2001 | 165 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 218 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 54 | 0.040 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2018 | 6 | 0.030 |
Why?
|
| Ileus | 1 | 2017 | 7 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 524 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 397 | 0.030 |
Why?
|
| Qc-SNARE Proteins | 1 | 2017 | 1 | 0.030 |
Why?
|
| Integrin alpha3 | 1 | 2017 | 18 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 47 | 0.030 |
Why?
|
| Serpins | 1 | 2017 | 31 | 0.030 |
Why?
|
| Exome | 1 | 2017 | 32 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 66 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 90 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 2016 | 9 | 0.030 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2016 | 6 | 0.030 |
Why?
|
| Folic Acid | 1 | 2017 | 33 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 89 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2017 | 37 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 98 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 46 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 138 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 112 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 245 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 168 | 0.030 |
Why?
|
| Perception | 1 | 2017 | 90 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 237 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2016 | 103 | 0.030 |
Why?
|
| Trefoil Factor-3 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 51 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 164 | 0.030 |
Why?
|
| Ischemia | 1 | 1996 | 83 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 115 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 43 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2015 | 132 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 87 | 0.030 |
Why?
|
| Pyrophosphatases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Microdissection | 1 | 2015 | 15 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 14 | 0.030 |
Why?
|
| Pyrones | 1 | 2015 | 6 | 0.030 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2015 | 19 | 0.030 |
Why?
|
| Uterus | 1 | 2015 | 31 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 28 | 0.030 |
Why?
|
| Male | 2 | 2020 | 13934 | 0.030 |
Why?
|
| Papio | 1 | 2015 | 81 | 0.030 |
Why?
|
| Quinolines | 1 | 2015 | 35 | 0.030 |
Why?
|
| Oxazines | 1 | 2015 | 19 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2014 | 5 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2014 | 31 | 0.030 |
Why?
|
| Vimentin | 1 | 2014 | 28 | 0.030 |
Why?
|
| DNA Repair | 1 | 2015 | 82 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 697 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 178 | 0.030 |
Why?
|
| Remission Induction | 1 | 2013 | 58 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 270 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 60 | 0.030 |
Why?
|
| Colposcopy | 1 | 2013 | 63 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1056 | 0.030 |
Why?
|
| DNA Damage | 1 | 2015 | 152 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 1255 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2015 | 631 | 0.030 |
Why?
|
| Diaphragm | 1 | 2013 | 16 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2013 | 26 | 0.030 |
Why?
|
| eIF-2 Kinase | 1 | 2013 | 29 | 0.030 |
Why?
|
| Peptides | 1 | 2015 | 296 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 24 | 0.020 |
Why?
|
| Splenectomy | 1 | 2013 | 44 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 51 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2013 | 37 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 208 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 536 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 2013 | 58 | 0.020 |
Why?
|
| Histones | 1 | 2013 | 96 | 0.020 |
Why?
|
| Fetal Proteins | 1 | 2012 | 3 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2012 | 12 | 0.020 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2012 | 9 | 0.020 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 11 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 194 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 163 | 0.020 |
Why?
|
| Intermediate Filament Proteins | 1 | 2012 | 21 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 48 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 71 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 490 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 124 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 477 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2011 | 7 | 0.020 |
Why?
|
| Formaldehyde | 1 | 2011 | 11 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2011 | 14 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 57 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 515 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 86 | 0.020 |
Why?
|
| Child | 1 | 2018 | 2291 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 154 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 410 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 1658 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 1022 | 0.020 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2007 | 4 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2007 | 292 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2006 | 7 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2006 | 30 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2006 | 60 | 0.020 |
Why?
|
| Luciferases | 1 | 2006 | 54 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2006 | 23 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2006 | 275 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 451 | 0.010 |
Why?
|
| Electrosurgery | 1 | 2001 | 15 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2001 | 13 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 2001 | 11 | 0.010 |
Why?
|
| Conization | 1 | 2001 | 11 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2001 | 14 | 0.010 |
Why?
|
| HIV Protease Inhibitors | 1 | 2001 | 14 | 0.010 |
Why?
|
| Recurrence | 1 | 2001 | 326 | 0.010 |
Why?
|